Recombinant
RabMAb

Anti-CLCN2 antibody [EPR6492(2)] (ab154798)

Overview

  • Product name
    Anti-CLCN2 antibody [EPR6492(2)]
    See all CLCN2 primary antibodies
  • Description
    Rabbit monoclonal [EPR6492(2)] to CLCN2
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC/IF or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human CLCN2. The exact sequence is proprietary.
    (Peptide available as ab218163)

  • Positive control
    • HT29 and HeLa cell lysates; mouse brain, mouse heart, mouse kidney, mouse spleen, rat kidney and rat spleen lysates; Human thyroid gland carcinoma tissue.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab154798 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 99 kDa.Can be blocked with CLCN2 peptide (ab218163).
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IP.
  • Target

    • Function
      Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.
    • Tissue specificity
      Ubiquitously expressed. Moderately expressed in aortic and coronary vascular smooth muscle cells and expressed at a low level in aortic endothelial cells.
    • Involvement in disease
      Defects in CLCN2 are associated with susceptibility to idiopathic generalized epilepsy type 11 (IGE11) [MIM:607628]. A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.
      Defects in CLCN2 are the cause of childhood absence epilepsy type 3 (ECA3) [MIM:607682]. ECA3 is a subtype of idiopathic generalized epilepsy (IGE) characterized by onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3 Hz spike waves on EEG. During adolescence, tonic-clonic and myoclonic seizures develop.
      Defects in CLCN2 are associated with juvenile absence epilepsy type 2 (JAE2) [MIM:607628]. JAE is a subtype of idiopathic generalized epilepsy (IGE) characterized by onset occurring around puberty, absence seizures, generalized tonic-clonic seizures (GTCS), GTCS on awakening and myoclonic seizures.
      Defects in CLCN2 are associated with juvenile myoclonic epilepsy type 8 (EJM8) [MIM:607628]. A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.
    • Sequence similarities
      Belongs to the chloride channel (TC 2.A.49) family. ClC-2/CLCN2 subfamily.
      Contains 2 CBS domains.
    • Cellular localization
      Membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Chloride Channel 2 antibody
      • Chloride channel protein 2 antibody
      • Chloride channel, voltage sensitive 2 antibody
      • CIC 2 antibody
      • CIC2 antibody
      • ClC-2 antibody
      • CLC2 antibody
      • Clcn2 antibody
      • CLCN2_HUMAN antibody
      • ECA2 antibody
      • ECA3 antibody
      • EG13 antibody
      • EGI11 antibody
      • EGMA antibody
      • EJM6 antibody
      • EJM8 antibody
      • PKA-activated chloride channel antibody
      see all

    Images

    • Immunohistochemical analysis of paraffin-embedded Human thyroid gland carcinoma tissue labeling CLCN2 with ab154798 at 1/50 dilution.
    • All lanes : Anti-CLCN2 antibody [EPR6492(2)] (ab154798) at 1/1000 dilution

      Lane 1 : HT29 cell lysate
      Lane 2 : HeLa cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 99 kDa

    • All lanes : Anti-CLCN2 antibody [EPR6492(2)] (ab154798) at 1/1000 dilution

      Lane 1 : mouse brain lysate
      Lane 2 : mouse heart lysate
      Lane 3 : mouse kidney lysate
      Lane 4 : mouse spleen lysate
      Lane 5 : rat kidney lysate
      Lane 6 : rat spleen lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 99 kDa

    References

    This product has been referenced in:
    • Sun L  et al. The CLC-2 Chloride Channel Modulates ECM Synthesis, Differentiation, and Migration of Human Conjunctival Fibroblasts via the PI3K/Akt Signaling Pathway. Int J Mol Sci 17:N/A (2016). WB ; Human . Read more (PubMed: 27294913) »

    See 1 Publication for this product

    Customer reviews and Q&As

    Application
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Blocking step
    H2O2 as blocking agent for 10 minute(s) · Concentration: 3% · Temperature: 25°C
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: EDTA pH8.6 20 min 100C
    Sample
    Human Tissue sections (small intestine)
    Specification
    small intestine
    Permeabilization
    No
    Fixative
    Formaldehyde
    Username

    Abcam user community

    Verified customer

    Submitted Aug 06 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up